GlassScriptPhysician profile
Thien Huu Hoang
NPI 1063904274
$5,310.65
in general payments reported to CMS, 2019-2025
31 companies · $2,686 in 2025
The $2,686 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.56 · 2022: $88.64 · 2023: $516 · 2024: $2,007 · 2025: $2,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,145 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,144.91 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $742.77 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $559.98 | 2023-2025 | Tepezza, Evenity, Prolia |
| Insulet Corporation | $550.67 | 2023-2025 | Omnipod |
| Lilly USA, LLC | $539.79 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $349.45 | 2024-2025 | Korlym |
| Madrigal Pharmaceuticals | $298.76 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $261.75 | 2024-2025 | Qutenza |
| Amneal Pharmaceuticals LLC | $232.71 | 2023-2025 | Unithroid |
| Cequr Corporation | $226.15 | 2023-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $224.34 | 2023-2025 | |
| Dexcom, INC. | $224.28 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.10 | 2022-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $164.19 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $96.10 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $84.26 | 2024-2025 | Tirosint, Licart, Flector |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $57.48 | 2024-2025 | |
| Janssen Biotech, INC. | $51.85 | 2023-2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $50.55 | 2024-2025 | Strensiq |
| Sequel Med Tech, LLC | $45.52 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $42.65 | 2025 | |
| Abbott Laboratories | $41.03 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $34.93 | 2025 | |
| Tolmar, INC. | $33.69 | 2025 | Jatenzo |
| Ascendis Pharma Endocrinology INC | $32.95 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $32.22 | 2024-2025 | Crysvita |
| Mannkind Corporation | $30.42 | 2024-2025 | |
| Rgh Enterprises LLC | $27.84 | 2025 | |
| Pfizer INC. | $21.99 | 2025 | |
| Horizon Therapeutics Plc | $14.93 | 2023 | Tepezza |
| Embecta Corp. | $13.24 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Medtronic, INC. | $13.06 | 2023 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thien Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.